Appareil pulmonaire
AcceleRET (BLU-667-2303 )
A Randomized, Open-Label, Phase 3 Study of Pralsetinib versus Standard of Care for First Line Treatment of RET fusion-positive, Metastatic Non-Small Cell Lung Cancer Cancer (BLU667-2303)
Paris
NICOLAS GIRARD